On September 23, METIS TECHBIO-P rose 6.85% in regular trading, trading at HKD 17.71/share, with turnover of approximately HKD 60.03 million. The rally was driven by multiple converging catalysts spanning corporate strategy, policy support, and business partnerships.

On the corporate front, co-founder and CEO Dr. Lai Caida recently delivered a keynote speech titled on Programmable Biology as AI's new frontier, emphasizing that the core competitive advantage in Biological AI lies in the continuous acquisition of high-quality experimental data and its conversion into model capabilities. He outlined a \"three-layer cake\" technical architecture for AI-driven drug development, with the foundational layer being a combined dry-lab and wet-lab data platform.

On the policy front, the 15th Five-Year Plan has formally designated AI-powered pharmaceuticals as a key priority for the medical industry, explicitly calling for the cultivation of high-value AI pharma application scenarios. On the business side, the company previously signed a joint venture agreement with Zhaoyan Bio to establish Zhaotai Zhiyao, building an mRNA drug innovation R&D and industrialization platform. The company's NanoForge platform has achieved targeted delivery to eight key human organs and tissues. In the first half of the year, METIS TECHBIO-P reported revenue of RMB 154 million, up 13,399% year-over-year, surpassing full-year prior revenue by 47%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)